Posted by Michael Wonder on 20 Feb 2024
US FDA accepts supplemental new drug application for Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for patients with previously treated KRAS G12C mutated locally advanced or metastatic colorectal cancer for priority review
20 February 2024 - BMS today announced that the US FDA has accepted for priority review the supplemental new drug application for Krazati (adagrasib) in combination with cetuximab for the treatment of patients with previously treated KRASG12C mutated locally advanced or metastatic colorectal cancer.
The FDA assigned a Prescription Drug User Fee Act goal date of 21 June 2024.
